HpVac is developing the anti-allergy asset HpVac-R13, for which it owns an exclusive license, and expects to start clinical trials during the course of 2024.
After successfully obtaining financing for its lead validation and lead optimization phases, HpVac is currently launching its Series A round (USD 10M+) for pre-IND and Phase I activities.
HpVac is currently open to industrial and/or financial partners to collaborate on the next phases of its development.
Partners will be able to rely on the HpVac's tested, solid expertise, based on over 20 years' experience in business and pharmaceutical development, and on the company's wide network of specialized consultants and CROs.
Interested parties are welcome to contact us on: info@hpvac.ch
The mode of action of HpVac-R13 suggests that it could be deployed against several indications of the atopic march, e.g. atopic dermatitis, allergic asthma and allergic rhinitis, as well as other indications such as IBD or celiac disease.
The prevalence of all possible indications is on the rise; 5-year CAGR forecasts range from 2.8% (ulcerative colitis) to 9.7% (allergic rhinitis). The worldwide health costs caused by these indications together may exceed 55 Billion USD in 20231), while the pharmaceutical industry struggles to find affordable and effective alternatives to current standard treatments.
1) GlobalData Plc, 2018.